[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fuchs-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fuchs-dystrophy":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,72,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100460465","phase-3-descemet-endothelial-thickness-comparison-trial-ii-100460465",false,"NCT05275972","Descemet Endothelial Thickness Comparison Trial II","Descemet Endothelial Thickness Comparison Trials (DETECT I & II)","DETECT II","Inclusion Criteria:\n\n* Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm\n* Peripheral endothelial cell count \\>1000 cells\u002Fmm2 in at least one quadrant\n* Good surgical candidate for either procedure as determined by the surgeon\n* Willingness to participate\n* Age greater than 18 years\n\nExclusion Criteria:\n\n* Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK\n* Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment\n* Other primary endothelial dysfunction such as PPMD\n* Visually significant optic nerve or macular pathology\n* Hypotony (Intraocular pressure \\\u003C10mmHg)\n* Any prior intraocular surgery other than cataract surgery\n* \\>3 clock hours of ANY anterior or posterior synechiae\n* \\>1 quadrant of stromal corneal vascularization\n* Inability to comply with post-operative instructions (i.e. unable to position)\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.",[27,28,29],"Fuchs","Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","RECRUITING","2026-05-06",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2023-01-23",{"date":38,"type":21},"2028-11-30",{"name":40,"class":41},"Stanford University","OTHER",8,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100488166","phase-1-study-to-assess-safety-and-tolerability-of-multiple-doses-of-eo2002-100488166","NCT05636579","Study to Assess Safety and Tolerability of Multiple Doses of EO2002","Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema","Inclusion Criteria:\n\nAll ocular criteria apply to the study eye unless otherwise noted.\n\n1. Age ≥ 18 years.\n2. Subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus).\n3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs' corneal dystrophy or pseudophakic bullous keratopathy.\n\nKey Exclusion Criteria:\n\nAll ocular criteria apply to the study eye unless otherwise noted.\n\n1. Other corneal disease\n2. Anterior chamber intraocular lens\n3. Sutured or scleral-fixated intraocular lens.\n4. Macular disease that in the investigator and\u002For sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.\n5. History of refractive surgery.\n6. History of Vitrectomy\n7. Descemet membrane detachment.\n8. History of uveitis or other ocular inflammatory disease.\n9. History of incisional glaucoma surgery (e.g.,trabeculectomy, glaucoma drainage implant).\n10. IOP \\>21 or \\\u003C7 mm Hg\n11. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.\n\n11\\. History of ocular neoplasm. 12. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20\u002F200).\n\n13\\. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.\n\n14\\. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.\n\n15\\. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.",{"count":51,"type":21},12,[53],"PHASE1","The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.",[56,57,58,28,29,59,60,61],"Corneal Edema","Corneal Endothelial Dystrophy","Endothelial Dysfunction","Bullous Keratopathy","Pseudophakic Bullous Keratopathy","Corneal Edema Pseudophakic","2025-12-02",{"date":64,"type":34},"2025-12-08",{"date":66,"type":34},"2022-11-08",{"date":68,"type":21},"2025-12-09",{"name":70,"class":41},"Asociación para Evitar la Ceguera en México",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":71},"100382373","oct-in-fuchs-dystrophy-100382373","NCT04258787","OCT in Fuchs' Dystrophy","Evaluating Corneal Edema in Fuchs' Endothelial Dystrophy Using Optical Coherence Tomography","Inclusion Criteria:\n\n* Damaged or diseased corneal endothelium from Fuchs' or PBK\n* Willingness to commit to required study visits\n\nExclusion Criteria:\n\n* Prior Endothelial Keratoplasty (EK) or any other surgery except uncomplicated cataract surgery\n* Presence of a condition that increases the probability for treatment failure (e.g., heavily vascularized cornea, uncontrolled uveitis)\n* Other primary endothelial dysfunction conditions (e.g., posterior polymorphous corneal dystrophy and congenital hereditary corneal dystrophy, iridocorneal endothelial syndrome)\n* Central sub-epithelial or stromal scarring that could impact post-operative clarity assessment\n* Peripheral anterior synechiae in the angle greater than 3 clock hours\n* Hypotony\n* Uncontrolled glaucoma\n* Visually significant optic nerve or macular pathology",{"count":20,"type":21},"OBSERVATIONAL","This is an observational study using optical coherence tomography (OCT) technology to quantify corneal edema in Fuchs' endothelial dystrophy and predict refractive shift from resolving corneal edema after surgical treatments.",[28,60],[27,60,84,85],"Optical Coherence Tomography (OCT)","PBK","2025-09-05",{"date":88,"type":34},"2025-09-09",{"date":90,"type":34},"2020-06-26",{"date":92,"type":21},"2028-06",{"name":94,"class":41},"Oregon Health and Science University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":71},"100583856","fecd-trace-fuchs-endothelial-corneal-dystrophy-trajectory-and-correlation-with-genotype-in-the-united-kingdom-100583856","NCT06881771","FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom","Investigating Genetic Causes and Molecular Mechanisms Responsible for Inherited Corneal Disease","FECD-TRACE","Inclusion Criteria:\n\n* Willing and able to provide informed consent for participation in the study\n* Willing to attend scheduled study visits and undergo a clinical examination\n* Willing to donate blood\u002Fsaliva samples\n* Fulfil the abovementioned cohort criteria\n\nExclusion Criteria:\n\n* Presence of a secondary cause for corneal endothelial dysfunction or oedema\n* Presence of clinically evident corneal oedema\n* History of concurrent corneal diseases\n* History of corneal surgeries, including corneal transplantation\n* Cognitive impairment or inability to provide informed consent for participation in the study",{"count":104,"type":21},500,"FECD-TRACE is an integral component of a large research program dedicated to Fuchs Endothelial Corneal Dystrophy (FECD) in the United Kingdom. This longitudinal, observational study aims to comprehensively characterize a cohort of younger research participants who have a genetic predisposition to developing FECD. By utilizing advanced anterior segment imaging techniques, the study will monitor these individuals over a span of several years, capturing phenotypic changes that reflect the progression of the disease. Concurrently, genetic biomarkers will be examined to establish correlations with the observed phenotypic changes. The primary objective of FECD-TRACE is to enhance our understanding of the intricate genetic mechanisms underlying FECD and establish connections between these genetic findings and clinical outcomes. Ultimately, this research strives to facilitate the development of personalized care approaches for individuals affected by FECD.",[28,29,107,108,109],"Fuchs' Endothelial Corneal Dystrophy of Bilateral Eyes","Corneal Dystrophy Fuchs","Corneal Dystrophy",[111,112,113,57],"Fuchs' Corneal Endothelial Dystrophy","FECD","Corneal Dystrophies","2025-03-11",{"date":116,"type":34},"2025-03-18",{"date":118,"type":34},"2024-02-01",{"date":120,"type":21},"2027-02-01",{"name":122,"class":41},"University College, London","Fuch's Dystrophy"]